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Patients with chronic kidney disease (CKD) often exhibit symptoms of anorexia and cachexia, which are associated with decreased
quality of life and increased mortality. Chronic inﬂammation may be an important mechanism for the development of anorexia,
cachexia, renal osteodystrophy, and increased cardiovascular risk in CKD. Ghrelin is a gastric hormone. The biological eﬀects of
ghrelin are mediated through the growth hormone secretagogue receptor (GHSR). The salutary eﬀe c t so fg h r e l i no nf o o di n t a k e
and meal appreciation suggest that ghrelin could be an eﬀective treatment for anorexic CKD patients. In addition to its appetite-
stimulating eﬀects, ghrelin has been shown to possess anti-inﬂammatory properties. The known metabolic eﬀects of ghrelin and
the potential implications in CKD will be discussed in this review. The strength, shortcomings, and unanswered questions related
to ghrelin treatment in CKD will be addressed.
1.Introduction
The cachexia syndrome in patients with chronic kidney
disease (CKD) consists of muscle wasting, anorexia, and
increased elevated energy expenditure. Cachexia is an
important risk factor for mortality in patients with CKD,
which is 100-fold to 200-fold higher than in the general
population. Cachexia, a common feature in many chronic
inﬂammatory diseases, is distinct from malnutrition, which
is deﬁned as the consequence of insuﬃcient nutrients [1].
Responses in malnutrition are adaptive, whereas those in
cachexia are maladaptive. In malnutrition, such as in simple
starvation, fats are preferentially utilized and lean body mass
is preserved. In cachexia, muscle mass is wasted and fats
are relatively underutilized. Anorexia, deﬁned as the loss of
desire for food, is prevalent in patients CKD. Anorexia in
CKD patients can arise from decreased taste and smell of
food, early satiety, dysfunctional hypothalamic membrane
adenylate cyclase, increased brain tryptophan, and increased
cytokine production. Anorexia reduces oral energy and
protein intakes and contributes to the development of
cachexia. Elevated resting energy expenditure was associated
with increased mortality and cardiovascular death in CKD
and was closely correlated with the prevalence of cachexia
among these patients [2]. To date, there is no eﬀective
therapy for cachexia in CKD. Nutritional strategies such as
caloric supplementation and appetite stimulants have been
largely unsuccessful. Thus, there is an urgent need for the
development of new therapeutic agents for this potentially
fatal complication of CKD [3].
2.EnergyMetabolisminCKD
New insights into the pathophysiolgy of cachexia in CKD
hold the promise of novel therapeutic strategies. One
important mechanism for cachexia in CKD is that elevated
circulating proinﬂammatory cytokines act on CNS and
regulate the release and function of a number of key
neuropeptides, thereby inﬂuence energy metabolism. Leptin
and central melanocortin systems have been suggested as
targets of cytokine action in the hypothalamus, which is a
critical regulator of food intake and energy homeostasis [4].
There are two distinct subsets of neurons that control food
intake in the hypothalamus. One subset of neurons produce
neuropeptide Y (NPY) that stimulates food intake while an
adjacent neuronal subset produces melanocortin peptides,
which inhibit eating. Circulating leptin and insulin decrease2 International Journal of Peptides
appetite by inhibiting NPY and agouti-related peptide
(AgRP), while stimulating the production of melanocortin
peptides in the hypothalamus. Inﬂammatory cytokines
induce anorexia by their central actions. Cytokines regulate
gastrointestinal activities, cause metabolic changes, aﬀect the
endocrine system, and modulate the neuropeptide proﬁle of
the hypothalamus, all of which can inﬂuence eating behavior
[1,5].Wehavedemonstratedthatcachexiainamousemodel
of CKD could be ameliorated by genetic or pharmacological
blockade of leptin and central melanocortin signaling via
the melanocortin receptor type-4 (MC4-R) [6]. However,
potential clinical utility of this approach is limited by the
need to deliver AgRP intracerebroventricularly. We then
examined the eﬀects of NBI-12i, a small molecule MC4-
R reverse agonist, in a mouse model of uremic cachexia.
Intraperitoneal injection of NBI-12i ameliorated uremic
cachexia. The protective eﬀects of NBI-12i may be due to
the normalization of the upregulation of uncoupling protein
expression seen in CKD mice [7]. These data underscore the
importance of melanocortin signaling in the pathogenesis
of uremic cachexia and demonstrate the potential utility of
MC4-R antagonists as a novel therapeutic approach.
3.GhrelinPhysiology
Ghrelin is a gut peptide that stimulates the production
of growth hormone (GH) from the pituitary gland [8].
Ghrelin, a natural ligand of the GH secretagogue receptor
1a (GHS-R1a), is secreted into the bloodstream primarily
from the stomach and small intestine. Ghrelin is mainly
degradedbythekidney[9].Inadditiontostomachandsmall
intestine, small amount of ghrelin has also been detected
in hypothalamic arcuate nucleus and many other tissues.
GHS-R1a is expressed by neurons in the arcuate nucleus
and the ventromedial hypothalamus. Ghrelin is a circulating
hunger hormone and is considered the counter regulatory
hormone for leptin. Ghrelin levels increase before meal and
decrease after meals. Ghrelin and synthetic ghrelin analogues
increase food intake by an action exerted at the level of
the hypothalamus. They activate cells in the arcuate nucleus
that include the orexigenic NPY neurons [10]. Ghrelin-
responsiveness of these neurons is both leptin- and insulin-
sensitive [11]. Ghrelin also activates the mesolimbic cholin-
ergic/dopaminergic pathways, a circuit that communicates
the hedonic and reinforcing aspects of natural rewards, such
as food and ethanol [12]. Most studies to date have focused
ontheeﬀectsofpharmacologicaldosesofghrelinanditsana-
logues in human and animal models. These eﬀects include
stimulation of GH-releasing activity, stimulation of ACTH
release, inhibition of gonadotropin secretion, stimulation
of appetite and positive energy balance, changes in gastric
m o t i l i t ya n da c i ds e c r e t i o n ,p r o t e c t i v ee ﬀects against gastric
mucosal injury, and modulation of pancreatic function and
glucose metabolism enhanced cardiovascular performance
viaGH-growth-likefactor(IGF-I)axis,aswellasmodulation
of immune system and bone biology [9, 13, 14].
Three distinguished ghrelin gene products, that is, acyl
ghrelin, des-acyl ghrelin and obestatin, have been identiﬁed.
Acyl ghrelin was identiﬁed as the endogenous cognate ligand
for the GHS-R1a [8]. The second endogenous cognate ligand
for GHS-R, des-Gln14-ghrelin, another novel 27-amino acid
peptide, is created by alternative splicing of the ghrelin
gene and constitutes one ﬁfth of ghrelin immunoreactivity
of the rat stomach [15]. Acyl ghrelin increases meal size
[16, 17]. Acyl ghrelin and GHRH are both endogenous
GH-releasing peptides. GHRH acts on the GHRH receptor,
distinct from GHS-R1a, to activate adenylate cyclase and
to increase intracellular cAMP, which serves as a second
messenger to activate subsequent signaling cascade [9].
In contrast, des-acyl ghrelin, lacking O-n-octanoylation at
serine 3, is also produced in the stomach and remains
the major molecular form secreted into the circulation.
Des-acyl ghrelin has been shown to actively participate in
food intake [18], gut motility [19], body size development
[19, 20], adipogenesis [21], insulin secretion and resistance
[22], and to increase tension of guinea pig papillary muscle
ex vivo [23], and cell proliferation and survival in vitro
[24, 25]. Des-acyl ghrelin was secreted in a highly regulated
manner in response to food deprivation in mice [26].
Intracerebroventricular (icv) administration of rat des-acyl
ghrelin to rats or mice stimulated feeding and induced
the expression of Fos, a marker of neuronal activation,
in orexin-expressing neurons of the lateral hypothalamic
area. Peripheral administration of des-acyl ghrelin to rats or
mice did not aﬀect feeding. Des-acyl ghrelin increased the
intracellular calcium concentrations in isolated orexin neu-
rons. Central des-acyl ghrelin may activate orexin-expressing
neurons, perhaps functioning in feeding regulation through
interactions with a target protein distinct from the GHS-
R1a [27]. The third ghrelin gene product, obestatin, a novel
23-amino acid peptide identiﬁed from rat stomach, was
derived from the mammalian prepro-ghrelin gene, which
also encodes ghrelin, by comparative genomic analyses
[28]. It was originally projected that obestatin binds to
an orphan G protein-coupled receptor, termed GPR39, to
inhibit food intake [28]. Obestatin induces early-response
gene expression in stomach, intestine, white adipose tissue,
liver, and kidney, suggesting its role as a gastrointestinal
and metabolic hormone [29]. Obestatin activates neurons in
several brain regions. Icv injection of obestatin inhibits thirst
and vasopressin secretion, suppresses food intake, regulates
sleep, decreases anxiety, and improves memory. Coupled
with the ability of obestatin to activate cortical neurons
and to stimulate the proliferation and downstream signaling
of human retinal pigment epithelial cells, these ﬁndings
underscore diverse functions of obestatin [30]. Disturbance
of circulating ghrelin and obestatin may have a role in the
pathogenesis of cachexia. Obestatin levels were signiﬁcantly
increased in cardiac patients with cachexia than patients
without cachexia and healthy controls [31]. Serum and saliva
ghrelin and obestatin levels were elevated in 24 hemodialysis
patients compared with age-matched healthy controls [32].
Obestatin manifested various biological functions, such as
improving memory performance, causing anxiolytic eﬀects
[33], inhibiting thirst in rats [34], activating cortical neurons
[35], stimulating proliferation of retinal pigment epithe-
lial cells in vitro [36], and profoundly inﬂuencing sleep
[37, 38].International Journal of Peptides 3
Serine-3 of ghrelin, which is acylated with an eight-
carbon fatty acid, octanoate, is inextricably required for the
multifaceted endocrine functions of acyl ghrelin. Despite the
crucial role for octanoylation in the physiology of ghrelin,
the lipid transferase that mediates this novel modiﬁcation
had remained unknown until recently. In 2008, ghrelin O-
acyltransferase (GOAT), attaching octanoate to serine-3 of
ghrelin, was identiﬁed and characterizedby twoindependent
research groups [39, 40]. Ghrelin seems to be the sole
substrate for GOAT. GOAT is located in the endoplasmic
reticulum, and the presumed donor for octanoylation is
octanoyl-CoA. Expression of GOAT was demonstrated to
be limited to the gastrointestinal tract, intestine, testis [39],
and the pancreas [40], the major ghrelin-secreting tissues.
The discovery of GOAT, an enzyme speciﬁc for octanylation
of ghrelin, may hold the promise of answering some major
questions about the unknown but important physiological
roles of ghrelin [41].
4.GhrelinandBody Composition
Muscle mass is important for physical ﬁtness and metabolic
regulation. Human observational study suggested that fast-
ing plasma ghrelin concentration is related to skeletal
muscle mass in healthy adults. After accounting for other
covariates, total body skeletal mass was a signiﬁcant negative
predictor of ghrelin concentrations [42]. Eﬀects of an
oral ghrelin mimetic on body composition and clinical
outcomes in 65 healthy older adults were analyzed. Over
12 months, the ghrelin mimetic MK-667 enhanced growth
hormone secretion, signiﬁcantly increased fat-free mass, and
was generally well tolerated [43]. In a longitudinal study,
relationship between body composition and plasma ghrelin
levels was investigated in a group of end-stage renal disease
(ESRD) adult patients. Changes in plasma ghrelin during 12
months of peritoneal dialysis treatment are associated with
changes in body composition. Markedly elevated plasma
ghrelin levels are found in advanced renal failure and
correlatewithfatmass[44].Ghrelinregulatesfatdistribution
and energy metabolism in lean tissues such as liver and
muscles. In liver, ghrelin induced a lipogenic and glucogenic
pattern of gene expression and increased triglyceride content
while reducing activated (phosphorylated) stimulator of
fatty acid oxidation, AMP-activated protein kinase (AMPK),
with unchanged mitochondrial oxidative enzyme activities.
In contrast, triglyceride content was reduced after ghrelin
administration in mixed (gastrocnemius) and unchanged in
oxidative(soleus)muscle.Inmixedmuscle,ghrelinincreased
mitochondrial oxidative enzyme activities independent of
changes in expression of fat metabolism genes and phos-
phorylated AMPK. Expression of peroxisome proliferator-
activated receptor-γ (PPAR-γ), the activation of which
reducesmusclefatcontent,wasselectivelyincreasedinmixed
muscle where it paralleled changes in oxidative capacities
[45]. Thus ghrelin induces tissue-speciﬁc changes in mito-
chondrial and lipid metabolism gene expression and favors
triglyceride deposition in liver over skeletal muscle. These
novel eﬀects of ghrelin in the regulation of lean tissue fat
distribution and metabolism could contribute to metabolic
adaptation to caloric restriction and loss of body fat.
5. Ghrelinand Inﬂammation
Chronic inﬂammation modulates ghrelin levels in humans
and rats [46]. In rat model of adjuvant-induced arthritis,
there is a compensatory variation of ghrelin levels that
relates to body weight adjustments [46]. Recovery of ghrelin
levels in the latter stage suggests an adaptive response and
may represent a compensatory mechanism under catabolic
conditions. Similar results were observed in patients with
rheumatoid arthritis [46]. Recent studies also suggest that
prostacyclin signaling regulates circulating ghrelin during
acute inﬂammation. Madison et al. have investigated the
mechanism of the regulation of ghrelin by inﬂammation.
Ghrelin levels fall in states of acute inﬂammation brought
about by injection of bacterial lipopolysaccharide (LPS).
They demonstrate that IL-1β receptor is expressed within
the gastric mucosa, but is not expressed by ghrelin cells.
The prostacyclin receptor was also expressed in the gastric
mucosa, and the majority of ghrelin-producing cells were
found to co-express this receptor. Mice with genetic deletion
of the IL-1β receptor do not suppress circulating ghrelin
levels with LPS administration [47]. Collectively, their data
support the notion that inﬂammation-induced decreases in
ghrelin are likely due to the action of IL-1β on cells within
the gastric mucosa that in turn produce prostacyclin as a
secondmessenger.Thesedataprovidefurthersupportforthe
potential role of ghrelin as a therapeutic agent in acute and
chronic inﬂammatory diseases.
6.Ghrelinand CKD
Conﬂicting results of circulating ghrelin levels in CKD have
been presented. Elevated plasma ghrelin levels were observed
in adult dialysis patients than those of age-matched controls
[48]. Szczepa´ nska et al. reported that plasma ghrelin levels
were similar in CKD children on dialysis compared with
childrenonconservativetreatmentandhealthycontrols[49].
In another study, adult hemodialysis patients showed similar
serum ghrelin levels whereas peritoneal dialysis patients
exhibited signiﬁcantly lower serum ghrelin concentrations
than predialysis CKD patients [50]. Multiple confounding
factors may contribute to these seemingly contradicting
ﬁndings. The two major forms of circulating ghrelin are
acylated (<10%) and des-acyl ghrelin [15, 51]. Acylated
ghrelin promotes food intake while des-acyl ghrelin induces
negative energy balance. Most of the investigators have
used the traditional radioimmunoassay method to analyze
the sum of both acylated and des-acyl ghrelin. However,
only plasma des-acyl ghrelin levels were elevated in CKD
patients compared with those patients with normal renal
functions. Recent studies have suggested that elevated des-
acyl ghrelin levels could be involved in the anorexia on
CKD patients [52]. Age and sex inﬂuence plasma ghrelin
levels. Plasma ghrelin levels were negatively correlated with
age in CKD patients [48]. Signiﬁcantly higher total ghrelin
levels were observed in female subjects [53]. Variations in4 International Journal of Peptides
residualrenalfunctionaﬀectghrelinmetabolism.Thekidney
degrades ghrelin. Increased total ghrelin levels in CKD are
primarily due to the decreased degradation of ghrelin in
the kidney [52]. Nutritional status of CKD patients may
also inﬂuence the metabolism of ghrelin. Assessment of
nutritional status has not been performed in most studies in
which chronic energy deﬁciency is evident in CKD patients.
In addition, nutrients may be introduced during dialysis in
CKD patients. The absorption of glucose and other nutrients
such as amino acids may inﬂuence plasma ghrelin levels
[50,54].Longitudinalstudies,byfollowingthesamepatients
cohort in terms of their serum ghrelin and nutritional status
[44], and by applying the discriminating ELISA assays to
diﬀerentiate acylated versus des-acyl ghrelin levels, are more
likely to reveal the pathophysiologic role of ghrelin in CKD.
Skeletal muscle mitochondrial dysfunction [55]a n d
insulin resistance [56, 57]h a v eb e e nr e p o r t e di nC K Da n d
may contribute to metabolic and cardiovascular morbidity
and mortality in advanced CKD patients. Administration
of ghrelin enhanced muscle mitochondrial enzyme activ-
ities and AKT-mediated insulin signaling independently
of food intake in healthy rats [45, 58]. Consistent with
these ﬁndings, a direct association was also shown between
insulin-mediated glucose metabolism and plasma ghrelin
concentrations in nondiabetic uremic patients undergoing
maintenance hemodialysis [59]. Eﬀects of ghrelin in skeletal
muscle mitochondrial oxidative capacity and AKT phospho-
rylation in a rat model of CKD were investigated. Results
indicated that ghrelin administration attenuated CKD-
associated reduction of mitochondrial oxidative capacity, as
reﬂected by representative mitochondrial enzyme activated.
These changes were associated with a higher transcriptional
expression of mitochondrial biogenesis stimulators such as
peroxisome proliferators activated receptor-γ-coactivator-1α
(PGC-1α)a n d- β (PGC-1β)[ 60]. Thus, eﬀects of ghrelin
on appetite and muscle mitochondria may improve muscle
metabolic and nutritional alternations in CKD.
7.GhrelinandItsAnalogues as
Potential Therapeutic Agents for
CKD-AssociatedCachexia
There is an urgent need for eﬀective appetite-stimulatory
therapies for CKD patients. Ghrelin is more potent than
any other orexigenic factors as it rapidly enhances food
consumption following injection in rodents [61]a n d
humans [62]. Results of recent ﬁndings bolster the potential
therapeutic application of ghrelin and its analogues as
an appetite stimulating and anabolic strategy in uremia-
associated cachexia and other types of disease-associated
cachexia. Ghrelin regulates metabolic balance and may
improve the cachetic condition through IGF-dependent and
IGF-independent pathways. The wide distribution of GHS-
R1a suggests multiple roles of ghrelin. Ghrelin and GHS-
R1a mediate anti-inﬂammatory signals in several cell types
[63, 64] and in various murine models of acute and chronic
inﬂammation [65]. The vagus nerve is an important link
between the nervous system and inﬂammation. It conveys
the immunologic state of the gastrointestinal tract to the
hypothalamus. Presence of GHS-R1a in aﬀerent neurons
of the nodose ganglion suggests that ghrelin signals are
transmitted to the brain through vagal aﬀerent nerves [66].
Ghrelin downregulates IL-6 and TNFα in sepsis via the
activation of vagus nerve [67]. Ghrelin and its analogue
increased food intake and improved lean body mass in
cancer rats [68]. Ghrelin treatment in uremia results in
improved lean mass accrual in part due to suppressed
muscle proteolysis and possibly related to anti-inﬂammatory
eﬀects. Ghrelin-treated nephrectomized rats had a decrease
in the expression of circulating inﬂammatory cytokines, IL-1
receptorandpro-hormoneconvertase-2,anenzymeinvolved
in the processing of pro-opiomelanocortin to the anorex-
igenic peptide alpha-MSH [69]. A single subcutaneous
injection of ghrelin (3.6nmol/kg) enhanced short-term (3-
day) food intake in a cohort of 9 adult CKD patients [70].
Subsequent report from the same group indicated that daily
administration of synthetic ghrelin (12mcg/kg) stimulated
foodintakeamong12dialysispatientsoveraperiodof7days
[71]. Importantly, energy expenditure was unchanged and
there was no subsequent compensatory reduction in energy
intake in these patients.
Given the complexity of the CKD-associated cachexia,
an integrated treatment approach is probably necessary.
Although appetite stimulants (e.g., megestrol acetate)
showed moderate success in improving patients’ appetites
[72], two short-term randomized, placebo-controlled trials
on ghrelin have renewed hope for the successful treatment
of uremic anorexia and wasting [70, 71]. In addition,
short-term administration of ghrelin and its analogues is
successful in treating several types of disease-associated
cachexia [60, 68, 69] and increases lean body mass in healthy
adults [42]. Although this new therapeutic approach holds
promise, however, several shortcomings and unanswered
questions need to be considered. Firstly, the studies were
of short duration and the long-term beneﬁts of ghrelin
and its analogues in CKD are unknown. We do not know
whether the reported improvement in appetite translates
into an improved nutritional status and a better outcome.
Secondly, long-term ghrelin therapy in CKD may eventually
lead to resistance to the eﬀects of ghrelin. Thirdly, given the
reported mitogenic potential of ghrelin [73], the possible
role of ghrelin in carcinogenesis needs attention. Another
concern that might diminish the enthusiasm for long-term
ghrelin treatment is the recent report that ghrelin infusion
induces lipolysis and insulin resistance [74]. Furthermore,
weight gain following ghrelin treatment is associated with
gain of fat mass without any change in lean body mass
[75]. In vitro experiments indicate that ghrelin stimulates
the diﬀerentiation of pre-adipocytes and antagonizes
adipogenesis, suggesting that ghrelin acts on adipocytes to
promote adipogenesis [76]. In summary, small-scale clinical
trials have provided encouraging evidence on the short-term
orexigenic eﬀects of subcutaneous ghrelin administration
in CKD patients. However, the clinical utility of ghrelin in
CKD will depend on the long-term outcomes in improving
appetite, muscle mass, and function as well as morbidity and
mortality.International Journal of Peptides 5
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